Highest Yielding Marijuana Cannabis Pot Stocks

Please note that this is a sister publication of WallStreetNewsNetwork ( http://WStNN.com ) and eventually everything on this site will be transferred over there.
by Fred Fuld III

You may have seen some of the major gains in some of the marijuana stocks and wanted to jump on the bandwagon. As an example, Cronos (CRON) has increased by 13% so far this year and Aurora (ACB) rose 26% even after experiencing a big drop during the last six months.

Maybe you are a relatively conservative investor and you want to receive a dividend in return for the risk you are taking. Fortunately, there are several cannabis stocks that provide investors with a yield.

Scotts Miracle-Gro Company (SMG) has a couple divisions in the marijuana industry. Its Hawthorne Gardening Co. subsidiary purchased General Hydroponics which makes and markets products for the pot growers. The company has also invested in the hydroponics company AeroGrow International (AERO) which markets to the small scale grower. Scotts’ current yield is 2.17%, with the latest dividend of 58 cents paid September 10 (today), an incense of 5.5% over the previous quarter. The dividend has increased on an annual basis since 2015.

AbbVie Inc. (ABBV), the marketer of Marinol also known as Dronabinol, a form of tetrahydrocannabinol, one of the main psychoactive ingredients of marijuana. The company has been paying quarterly dividends and has increased the annual dividend every year since 2013. AbbVie’s annual forward dividend yield is 6.28%. The company’s most recent dividend is $1.07 per share, which will be paid to investors on November 15, 2019 to shareholders of record on October 11.

Innovative Industrial Properties Inc. (IIPR), which trades on the New York Stock Exchange,  owns, manages, and leases properties to state licensed cannabis growing facilities. Annual dividends since 2017 were 55 cents, $1.20, and $2.40. The dividends are paid quarterly, currently 60 cents per share, up from 45 cents for the previous quarter, an increase of 33%. The company pays a dividend yield of 2.79%.

Altria (MO) is the tobacco company that manufactures and markets cigarettes and smokeless tobacco. The company invested over a billion dollars in Cronos Group (CRON), the Canadian marijuana company. The stock has a forward yield of 7.9%.

Molson Coors (TAP) is the seventh largest brewer in the world. The company is in partnership with HEXO (HEXO) to produce cannabis-infused beverages in Canada. Molson Coors yields 4.03%.

Horizons Marijuana Life Sciences Index ETF (HMLSF) is an exchange traded fund that invests in many companies involved in the marijuana industry. It has a yield of 7.54%.

Constellation Brands (STZ), the beer, wine, and liquor producer, has a significant ownership in the Ontario, Canada based cannabis company Canopy Growth (CGC). Constellation has a dividend yield of 1.44%.

Let’s hope some of these stocks get high, and provide you with a smoking portfolio.

Don’t forget to read:

Exclusive Interview with Chet Billingsley CEO of Mentor Capital on the Marijuana Industry

Is Apple Getting into the Marijuana Industry?

Disclosure: Author owns CGC and a long option position in ACB.



INVESTMENT TRIVIA 2019  
 
MAKES A GREAT GIFT!!!

Exclusive Interview with Chet Billingsley CEO of Mentor Capital on the Marijuana Industry

The following fascinating and informative interview was provided by Chet Billingsley, the Chairman, CEO, and founder of Mentor Capital, Inc., a public operating company that invests in pre-IPO cannabis related businesses. He did his undergraduate work at West Point. He later received a Master’s Degree in Applied Physics at Harvard University with concurrent study at Harvard Business School, and at MIT studying proton radiology. He is also a founding director and officer of the board of directors of the Nevada Cannabis Industry Association.

The discussion includes the following:

• What has happened in the cannabis industry during the last five years
• Why high excise taxes can cause the illegal market to continue
• Tilray and the Canadian market
• Why low excise taxes caused the legal Canadian marijuana market to grow
• The US cannabis regulatory scene
• Beer companies buying interests in marijuana businesses
• Tobacco companies getting into the marijuana businesses
• The growth of the medical marijuana market versus the recreational marijuana market
• Cannabis versus opiates
• Cannabeer and canabeverages
• The cannabis sub-industries, such as edibles, local delivery services, etc.
• And much more extensive interesting information!

To stream the interview, click:

HERE

All opinions are those of the interviewee, and do not represent the opinions of this website or the interviewer. Neither this website, nor the interviewer, nor the interviewee are rendering tax, legal, or investment advice in this interview. No investment advice is expressed or implied. No recommendations are made to buy, sell, hold, or short any security. All information is provided for education and general information only.

Disclosure: Interviewer owns shares of MNTR and has a short position in TLRY.

Many Marijuana Stocks Jumped 35% Today: Will They Continue to Get High or Go Up in Smoke?

If you thought that stocks in all the sectors seemed to be drifting downwards recently, you probably didn’t notice that the marijuana industry has been smoking.

For example, Cannabis Sativa (CBDS) jumped over 36% today. This is the company that Gary Johnson, the Libertarian presidential candidate, resigned from in January as CEO and Director, in order to run for president.

General Cannabis (CANN) rose by 31%, Cannabis Science (CBIS) went up by 29%, and Medical Marijuana (MJNA) went up by about 21%.

So what’s the reason for all this activity? The upcoming election. Marijuana legalization in some fashion is on the ballot in ten states, which is a record in terms of marijuana measures in one election.

The states that are involved are as follows:

Arizona
Arkansas
Arkansas
California
Florida
Maine
Massachusetts
Montana
Nevada
North Dakota

Some measure just involved medical marijuana, such as Arkansas and Florida. Other states have measures to legalize recreational marijuana, in addition to medical marijuana. Most investors are looking at Proposition 64 in the state of California, due to the size of the state’s population. Many investors believe that if California legalizes, then the cannabis stocks will take off.

Marijuana Stock Index

Look at the above chart of the Marijuana Stock Index. Back in late 2013, the pot stocks skyrocketed. Many investors in the medical arena became millionaires almost overnight, at least on paper.

The companies that make up this list are as follows:

Advanced Cannabis Solutions	CANN
Cannabis Sativa	CBDS
Cannabis Science	CBIS
GreenGro Technologies	GRNH
GrowLife Inc.	PHOT
Hemp Inc.	HEMP
mCig	MCIG
Medical Marijuana	MJNA
Agritek Holdings (MediSwipe)	AGTK
Pharmos Corp.	PARS
Planda Biotech	PLPL
Psychemedics	PMD
Solvay SA	SVYZY
Terra Tech	TRTC
Valeant Pharmaceuticals	VRX

One thing to keep in mind before investing in these stocks are that most of them are very low cap and extremely speculative.

If you are looking for a list of over 120 stocks that are connected to the marijuana industry in some way, go HERE.

It remains to be seen what will happen to these stocks, or what happens with the ballot measures, for that matter. Just remember, if you invest in a small cap stock, be prepared to lose it all.

Disclosure: Author owns CBDS, HEMP, and MJNA.

Exclusive Interview with Rob Hunt of the Largest Private Equity Cannabis Fund

The following fascinating interview was provided by Rob Hunt, a partner and the Lead Industry Executive at Tuatara Capital, the largest private equity fund in the cannabis industry. He also has an extensive background in cannabis business in Colorado, Massachusetts, New Hampshire and Maine as well.

Rob  Hunt has more than 15 years of experience in the cannabis industry as an attorney, a consultant, and a serial entrepreneur. Rob is currently a Partner, and the Lead Industry Executive of Tuatara Capital.

Mr. Hunt was formerly the Chairman of the Coalition for Responsible Patient Care, based in MA, where he spearheaded the initiative to help develop and implement the fledgling medical cannabis market in the Commonwealth. He was the principal developer of cannabis.org, a website focused on changing the scheduling of cannabis away from being a schedule I drug on the Federal Government’s list of controlled substances, Rob still authors all of the written commentary on the cannabis.org Facebook page where he has an audience of close to 20,000 readers.

We cover a lot in this interview, including:

• The California marijuana proposition
• Why marijuana has remained illegal for so long
• The current credit card ban on dispensaries 
• Opinion on publicly traded cannabis stocks
• Crowdfunding for marijuana related companies
• Willie Nelson's brand of marijuana
• Advice for investors interested in allocating funds to the cannabis industry
• Advice for those who are interested in setting up a marijuana startup

The Interview

You will certainly enjoy all this great information that Rob Hunt provides.

To stream the interview, click:

HERE

You can download as an mp3 by right-clicking here and choosing "save as."

More information about Tuatara Capital can be found HERE.


Let us know what you think about this interview by entering your comments in the comment section below. You can also check out the stocks in the WallStreetNewsnetwork.com Marijuana Stock Index.

All opinions are those of Rob Hunt, and do not represent the opinions of Stockerblog.com or the interviewer. Neither Stockerblog nor the interviewer nor the interviewee are rendering tax, legal, or investment advice in this interview.

Nasdaq Denies Cannabis Technology Company MassRoots; Shuns the Regulated Cannabis Industry

Denver, CO (May 25, 2016): MassRoots (OTCQB: MSRT), one of the largest and fastest growing technology platforms for the cannabis industry, received notification on Monday, May 23, 2016, that the Nasdaq will be denying MassRoots’ application for listing. The Nasdaq determined that as MassRoots may be deemed as aiding and abetting the distribution of an illegal substance, they are unwilling to proceed with MassRoots’ listing application. MassRoots plans to appeal the staff decision to the Nasdaq Listing and Hearings Review Panel.

“With this decision, the Nasdaq has set a dangerous precedent that will prevent nearly every company in the regulated cannabis industry from listing on a national exchange. This will have ripple effects across the entire industry, making it more difficult for cannabis entrepreneurs to raise capital and slow the progression of cannabis legalization in the United States,” stated MassRoots CEO Isaac Dietrich. “This decision must not be allowed to stand and we’re asking every cannabis investor, business, activist and supporter to write a brief note to the Nasdaq in support of our appeal here.”

“If we were a social network for tobacco users or alcohol consumers, the Nasdaq would likely be moving forward on our application even though alcohol and tobacco cause far more deaths and societal damage than cannabis ever will.  Moreover, the Nasdaq has already listed at least 4 biotechnology companies that extract compounds from the cannabis plant for scientific research – actually touching the plant as part of their business model,” continued Dietrich. “We believe the Nasdaq has inappropriately denied our application and look forward to making our case not just to the Nasdaq Listing and Hearings Review Panel, but directly to the American public.”

MassRoots has requested the Nasdaq’s denial letter in writing and will file an 8-K within 4 business days of receipt. The Company plans to appeal the Nasdaq’s decision shortly thereafter. MassRoots will not be affecting a reverse stock split unless its appeal from the Nasdaq is granted.

About MassRoots

MassRoots is one of the largest and most active technology platforms for cannabis consumers, businesses and activists with 900,000 users. It is proud to be affiliated with the leading organizations in the cannabis industry, including the ArcView Group and National Cannabis Industry Association. MassRoots has been covered by the Financial Times, Forbes, Fox Business, Bloomberg, Fortune, and CNBC. For more information, please visit MassRoots.com/Investors.

This information does not constitute an offer to sell or a solicitation of an offer to buy securities or assets of MassRoots. All information presented herein with respect to the existing business and the historical operating results of MassRoots and estimates and projections as to future operations, the success of events that we are attending, and other information, is based on materials prepared by the management of MassRoots and involve significant elements of subjective judgment and analysis which may or may not be correct. While the information provided herein is believed to be accurate and reliable, MassRoots makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. In furnishing this information, MassRoots reserves the right to amend or replace some or all of the information herein at any time and undertakes no obligation to provide the recipient with access to any additional information.  

Forward-looking Statements:

Certain matters discussed in this announcement contain statements, estimates and projections about the growth of MassRoots' advertising business, potential partnerships, and our related business strategy. Such statements, estimates and projections may constitute forward-looking statements within the meaning of the federal securities laws. Important factors that could cause our actual results to differ materially from those anticipated by the statements made herein include, among others, the success of our advertising initiatives, the continued growth and engagement of our user base, our ability to work with partners of the Company, and unforeseen technical or other problems or issues that could affect the performance of our products or our business. Further information on our risk factors is contained in our filings with the SEC, including the Amendment to our S-1 Registration Statement filed on October 29, 2015. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. MassRoots undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The recipient of this information is cautioned not to place undue reliance on forward-looking statements.

Weeding Out the Best Pot Stock: GW Pharmaceuticals

Headquartered in Salsbury, United Kingdom, GW Pharmaceuticals (NASDAQ:GWPH) uses its proprietary cannabinoid product platform to create and develop new therapeutics that can be used for a variety of treatments. The company's therapeutics, along with current and proposed treatments, include:

·      Sativex® for treating chronic cancer pain and multiple sclerosis spasticity

·      Epidiolix® for the treatment of childhood epilepsy, Dravet syndrome, and Lennox-Gastaut syndrome

·      Cannabidivarion for treating epilepsy

·      GWP42003 for treating ulcerative colitis and schizophrenia

·      GWP42004 for treating type-2 diabetes

·      GWP42002: GWP42003 for treating glioma, a tumor that starts in the brain or spine

One important development is that Sativex® was given Fast Track designation by the FDA for the treatment of chronic cancer pain in patients with advanced cancer who are not responding to opioid therapy. It is currently in a Phase 3 program for cancer pain with the FDA. Sativex® is already approved in 26 countries for spasticity caused by multiple sclerosis.

Strong Cash Position and Growing Revenues

In an industry where most companies don't even report revenues, GW has been generating revenues for years. For the latest reported quarter, revenues were up by 4.9%. Although the company has been generating losses, it has a huge cash cushion from its secondary offering in June of this year, netting the company $118 million, an increase of 342% in cash position over fiscal year end last year.

GW  in GBP 000's	6/30/2014	6/30/2013*	% Change
Revenue	7,611	7,258	4.9%
Cash	168,268	38,069	342.0%
Total Equity	157,774	35,402	345.7%

Balance sheet data as of 9/30/2013, fiscal year end

Revenue Growth

Revenue growth was primarily due to an increase in Sativex product sales generated by a rise in shipments to the company's commercial partners. In addition, total net revenues were helped by an increase in income from license, collaboration, and technical access fees.

Net loss went from GBP 2.028 million to GBP 6.928 million, due to a higher cost of sales from the higher volume of inventory shipped, an increase in research and development expenditures, and a rise in administrative expenditures caused by increased staffing expenditures and an unrealized loss on foreign exchange.

Inventories have remained constant over last year, at roughly GBP 4.7 million. In regards to guidance, the company expects strong double digit revenue growth for 2014.

Business Developments

Epidiolex®

FDA Authorized Physician-Led Access Program with about 100 children now receiving treatment in the United States at six hospital locations.

Orphan Drug Designation, Fast Track Designation were granted. An Investigational New Drug Application  has been opened with the FDA for the treatment of Dravet Syndrome. An additional Phase 3 trial is on track to begin in 2015.

Orphan Drug Designation was granted by the FDA for treating Lennox-Gastaut Syndrome. Phase 3 trials are on track to begin in 2015.

The company is collaborating with New York State and Georgia for Epidiolex clinical trials for epilepsy.

Sativex®

Phase 3 cancer pain data is expected to be released at the end of 2014, which would lead to an FDA New Drug Application.

Cannabidivarin

A Phase 2 trial for epilepsy should begin at the end of 2014 or the beginning of 2015.

Competitiion

Competition for this company could be looked at several ways. It could be examined as a biotech company, such as Biogen (NASDAQ:BIIB) and Questcor (NASDAQ:QCOR).

Or it could be looked at as a medical marijuana company, of which there are dozens. However, most of the other companies in this field are microcap stocks and penny stocks. The nearest competitors, based on large market cap, are Solvay SA (OTC:SVYZY), at a $13 billion market cap, which produces Marinol, a form of the primary marijuana ingredient tetrahydrocannabinol, commonly known as THC, and Valeant Pharmaceuticals Intl.            (NYSE:VRX), at a $42 billion market cap, which  distributes nabilone/Cesamet, a form of synthetic THC. Yet, in both of these cases, the THC drug is only a small part of their business.

If you are looking for other competitors, you can find a list of over 100 marijuana stocks at WallStreetNewsNetwork.com, along with information on the Stockerblog.com Marijuana Stock Index.

Timeliness

In the recent November election, Alaska, Oregon, and the District of Columbia have legalized the recreational use of marijuana. However, what is more important, and not many realize, is that 23 states have already legalized the use of medical marijuana.

Summary

GW Pharmaceuticals is a worldwide leader in the development of plant derived cannabinoid therapeutics.

GW is one of the few medical marijuana stocks with a market cap of over a billion dollars.

The company has been in business for 15 years and has produced the first marijuana related prescription drug, Sativex.®

It recently raised $118 million in a secondary offering.

Revenues for the latest reported quarter were up 4.9%.

Conclusion

GW has had a heck of a run this year, doubling in share price, so an investor obviously has market risk, and considering the speculative nature of the stock, if the stock market tanks, this stock could suffer much more than the average stock.

As is typical for many biotech companies, GW is not generating earnings yet. On the plus side, the company is increasing quarterly revenues on a year over year basis and has several therapeutic products in the pipeline. In addition, it is flush with cash.

So for investors that are willing to take the risk, and want to participate in the medical marijuana industry, you can't find a more solid pure play than GW Pharmaceuticals.

Disclosure: Author did not have any positions in any of the above at the time the article was written and has no plans to do so in the next 72 hours. 

By Stockerblog.com

Marijuana Stocks Crash in April

If you have been following the Stockerblog.com Marijuana Stock Index, which can be found at WallStreetNewsNetwork.com, over the last few months, you would notice that the pot stocks increased substantially during the first couple months of the year. However, during the month of March, the cannabis companies started to drop off, and in April, they really tanked.

According to the Marijuana Index, a dozen of the 21 stocks in the index dropped in excess of 30% over the last couple months, with several dropping by over 50%. For example, Advanced Cannabis Solutions (CANN) dropped by 53%, Cannabis Science Inc. (CBIS) dropped by a similar amount, and CannaVEST (CANV) fell by 87%.

The overall Marijuana Stock Index tanked by 43% during the last two months, whereas the S&P 500 was up by 1%. Interestingly, the Marijuana Stock Index is still outperforming the S&P 500 from the beginning of the year, with the Marijuana Index up 17% and the S&P up just 2%. Some of the stock are still up substantially from the beginning of the year in spite of the March and April drop, with more than ten rising over 100%.

To see the free list of all 21 stocks in the entire Stockerblog.com Marijuana Stock Index, go to WallStreetNewsNetwork.com. Also available is the Big List of marijuana stocks, which has over 100 cannabis stocks.

Disclosure: Author didn't own any of the above at the time the article was written. 

By Stockerblog.com

WallStreetNewsNetwork Marijuana Stock Index Up 40% for 1st Quarter

Marijuana stocks are still getting high. The WallStreetNewsNetwork.com Marijuana Stock Index was up a respectable 40% for the first quarter of this year, significantly outperforming the S & P 500, which was up only about 1.3% for this quarter. 

 
This is in spite of the fact that some cannabis companies experienced a huge drop this month. Interestingly, these were the higher priced stocks. For example, Advanced Cannabis Solutions    (CANN) dropped from 33.15 to 29.99, Cannabis Sativa Inc.   (CBDS) dropped from 11 to 7.85, and one of the biggest drops, CannaVEST (CANV) tanked from 147 to 38 per share.

There were some risers this month, such as mCig    (MCIG), which went from 0.46 a share to 0.74, and Terra Tech    (TRTC), which rose from 0.52 to 1.14.

Overall, most of the pot stocks were down for the month of March, but up for the quarter. If you look at the chart, you will notice that the weed stocks appear to have topped out, or at least taking a rest. 

For a list of the stocks in the WallStreetNewsNetwork.com Marijuana Stock Index or the BIG LIST of marijuana stocks, which now has over a 100 listings, go to WallStreetNewsNetwork.com.  

Disclosure: Author owns TRTC.

By Stockerblog.com

The Growth of the Medical Marijuana Industry and the Stocks that Participate

In November of 2012, the United States began the next revolution in American history. But this isn’t the railroad boom of the industrial revolution, or the booming importance of the Internet in the technology revolution. Instead, states like Colorado and Washington passed laws in 2012 that will pave the way for the medical marijuana revolution and will change how the nation accepts cannabis culture. But along with users who enjoy the opportunity to use marijuana for personal use, there is also a huge opportunity for investment for those that are looking to make a large financial gain.

Tax Revenues

Aside from all of the medical marijuana users who enjoy using for personal reasons, governments have also gotten ‘high’ after seeing the amount of money the industry turns over. In 2012, Colorado estimates that it brought in nearly $200 million in tax revenues. For a nation that is struggling to remain atop of the world economies, this is an eye-opening number. For those that are looking to invest, these numbers are important to keep in mind due to the value that they have on the national economy. If something is so profitable and helps the country dig into its national debt, it will only rise in value as it becomes more acceptable throughout the rest of the country. This garners amazing investment opportunities for those looking to invest in the marijuana industry.

Jobs

Aside from the money, the medical marijuana industry provides jobs for people. The larger the system gets, the more people are needed to work in the process of growing, harvesting, distributing and selling marijuana. If the tax revenue wasn’t enough to peak the interest of the government (hint, it is), then seeing the unemployment rate drop and even further bolstering the economy is another added benefit to keep in mind with the legitimacy of cultivating marijuana. This is an added safety net of concern for those looking to invest in the medical cannabis arena.

Establishment Support

Lastly, marijuana is no longer looked at with such negativity and stigmatized opinions. Influential names across America like US Attorney General Eric Holder, who has proposed more leniency for drug offenders, CNN’s Dr. Sanjay Gupta support of medical marijuana legalization, and many more high-ranking officials have voiced their opinion on the financial and health benefits that medicinal marijuana provides. Even major health journals, such as Nutricula Magazine has espoused the legalization of marijuana for its health benefits.

Investment Opportunities

If you are an investor who is considering buying stocks in medical marijuana, consider that a lot is weighing in favor of the huge growth of the industry. Like anything, there is risk when investing. However with the financial, employment and health benefits that medicinal marijuana provides, the industry has already begun to catch enough momentum that it has captured the eyes of investors.
Most of the companies related to medical marijuana are very low cap stocks, according to the free list of over 20 marijuana stocks at WallStreetNewsNetwork.com. However, for the medical use of marijuana and its derivatives, there are larger companies that produce such products as Marinol, which is synthesized THC, also known as dronabinol, and available by prescription in the US. This is a product of Solvay SA (SVYSF). However this is just a small part of this large chemical conglomerate.
Nabilone, marketed as Cesamet, is produced by Valeant Pharmaceuticals International (VRX), which trades on the New York Stock Exchange. Nabilone, a synthetic cannabinoid, is used to treat chemotherapy-induced nausea and vomiting, anorexia, and weight loss in AIDS patients. Valeant also markets Fluorouracil, a cancer treatment drug, and Diastat, a seizure drug. This $31.5 billion market cap stock trades at 7.87 times sales. Revenues for the latest quarter were up 33.6%, however, earnings were negative.

GW Pharmaceuticals (GWPRF) produces Sativex, an oral spray with tetrahydrocannabinol and cannabidiol, which is used to treat multiple sclerosis patients, and also for treating pain in cancer patients. This $137 million company trades at three times sales. Revenues were down 34% for the latest quarter.

Some of the companies in this industry have already made major moves. For example, Medbox, Inc. (MDBX), which makes machines that can dispense medication and medical marijuana to individuals based on biometric identification, has risen from about $2 a share a year ago to $35 a share today. Other microcap medical marijuana-related stocks that have recently started to move up are Cannabis Science Inc. (CBIS), Medical Marijuana Inc. (MJNA) which prints its stock certificates on hemp paper, CannaVEST Corp. (CANV), and Cynapsus Therapeutics Inc. (CTH.V). These are extremely low capitalization stocks that should be considered extremely speculative.

To see the complete free list of over twenty marijuana stocks, which shows the symbol, PE ratio, price sales ratio, yield, market capitalization, and business description, go to WallStreetNewsNetwork.com.



Disclosure: Author owns MJNA.

By Stockerblog.com

Marijuana Soda Pop

Dixie Elixirs and Edibles is a company that makes all kinds of marijuana and cannabis products, such as lozenges, soda, and massage oils. Dixie is a brand of Red Dice Holdings, a portfolio company of Medical Marijuana Inc. (MJNA). Several cannabis companies were mentioned in one of our previous articles about marijuana stocks.

Many of these companies started to skyrocket after the elections that legalized marijuana in Washington and Colorado. To see the complete free list of over twenty marijuana stocks, which shows the stock ticker symbol, PE ratio, price sales ratio, yield, market capitalization, and business description, go to WallStreetNewsNetwork.com.

Marijuana Stocks Get High After the Election

On November 6, voters in Colorado and Washington approved legislation that allows for the recreational use of marijuana, and Massachusetts legalized marijuana for medicinal use. Investors responded by causing the prices of several micro cap stocks connected to the cannabis and medical marijuana industry to get high. Some of the stocks that were smoking, just on Friday alone, were Cannabis Science, Inc. (CBIS) up 29%, Converted Organics Inc. (COIN) up 23%, Cynapsus Therapeutics Inc. (CTH.V) up 11%, GreenGro Technologies, Inc. (GRNH) up 183%, Hemp, Inc. (HEMP) up 9%, Medbox, Inc. (MDBX) up 23%, Rapid Fire Marketing, Inc. (RFMK) up 17%, and Tranzbyte Corporation (ERBB) up 31%.

Most of the companies related to marijuana are very low cap stocks, according to the free list of over 20 marijuana stocks at WallStreetNewsNetwork.com. However, for the medical use of marijuana and its derivatives, there are larger companies that produce such products as Marinol, a trademark of Solvay SA (SVYSF) and Nabilone, marketed as Cesamet by Valeant Pharmaceuticals International (VRX), which trades on the New York Stock Exchange. Nabilone, a synthetic cannabinoid, is used to treat chemotherapy-induced nausea and vomiting, anorexia, and weight loss in AIDS patients.

Valeant also markets Fluorouracil, a cancer treatment drug, and Diastat, a seizure drug. This $16.4 billion market cap stock trades at 613 times earnings, and five times sales.

Psychemedics Corporation (PMD) has a PE ratio of 19.15, a price sales ratio of 2.41, and pays a generous yield of 5.2%. This $60.47 million market cap company is a provider of marijuana testing and other drug testing services.

GW Pharmaceuticals (GWPRF) produces Sativex, an oral spray with tetrahydrocannabinol and cannabidiol, which is used to treat multiple sclerosis patients, and also for treating pain in cancer patients. This $121 million company trades at 3.5 times sales.

To see the complete free list of over twenty marijuana stocks, which shows the stock ticker symbol, PE ratio, price sales ratio, yield, market capitalization, and business description, go to WallStreetNewsNetwork.com.

Disclosure: Author didn't own any of the above stocks at the time the article was written.

By Stockerblog.com